REVIEW

Anti-Mullerian Hormone (AMH) as a Novel Marker for Ovarian Function: A Review

Sianny Herawati

Sianny Herawati
Department of Clinical Pathology, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia. Email: siannyherawati@yahoo.com
Online First: August 01, 2019 | Cite this Article
Herawati, S. 2019. Anti-Mullerian Hormone (AMH) as a Novel Marker for Ovarian Function: A Review. Bali Medical Journal 8(2). DOI:10.15562/bmj.v8i2.1372


Background: Anti-Mullerian Hormone (AMH) is a homodimeric glycoprotein linked by disulfide bonds which belongs to the Transforming Growth Factor (TGF) beta superfamily. AMH is produced by gonadal tissue namely testicular Sertoli cells and ovarian granulosa cells especially pre-antral and antral follicles. AMH involved in embryonic sexual differentiation in male, while it has an inhibitory effect on primordial follicle recruitment and responsiveness of the growing follicles to FSH, in female. Current studies show promising clinical utilities of AMH measurement in predicting ovarian function.

Objective: This review aims to explore further about the physiology of AMH and its role as a novel marker for ovarian function.

Method: A review of relevant literature was performed to elaborate AMH involvement in ovarian function. A total of 14 qualified published literature of all years until 2018 were collected from several electronic database and manual search and included in this review.

Results: AMH level reflected ovarian follicular reserve, an important indicator in infertility treatment (assisted reproduction technique) and a sensitive marker for ovarian aging. AMH is also a valuable tool in diagnosis and recognition of recurrence granulosa cell tumors, and a marker of ovarian dysfunction particularly polycystic ovary syndrome. A low circulating AMH level is observed in obesity and male with fertility problems.

Conclusion: AMH level can be used as primary or supplementary markers to aid in the diagnosis and treatment of several reproductive related conditions in males and females. A set of guidelines about sample storage and handling and age-specific standardized reference values are needed to optimize clinical application of AMH.

References

La Marca A, Volpe A. Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clinical Endocrinology. 2006; 64:603-610.

Aboulghar M. Anti-mullerian hormone in the management of infertility. Middle East Fertility Society Journal. 2014; 19:1-7.

Broer SL Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update. 2014; 20(5):688-701.

Karkanaki A, Vosnakis C, Panidis D. The Clinical significance of anti-Mullerian hormone evaluation in gynecological endocrinology. Hormones. 2011; 10(2):95-103.

Beineke M. Anti Mullerian Hormone (AMH) is an indicator of ovarian functional reserve. Bioscientia. 2008; 1-4.

Durlinger ALL, Visser JA, Themmen APN. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. 2002; 124:601-609.

La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian Hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Human Reproduction Update. 2010; 16(2):113-130.

Naafs MAB. Measurement of the Anti-Mullerian Hormone (AMH) in Endocrinology: a Mini-Review. Invest Gynecol Res Women’s Health: 2017; 1-6.

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WM, Anderson RA. The physiology and clinical utility of anti-Mullerian hormone in women. Human Reproduction Update. 2014; 20(3):370-385.

Freeman EW, Gracia CR, Sammel MD, Lin H, Leong Lim LC, Strauss JF. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertility and Sterility. 2007; 87(1):101-106.

Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17.120 women presenting to fertility centers within the United States. Fertility and Sterility. 2011; 95(2):747-750

Lie Fong S, Visser JA., Welt CK, de Rijke YB, Eijkemans JC, Broekmans FJ, Roes EM, Peters WHM, Hokken-Koelega ACS, Fauser BCJ, Themmen APN, de Jong FH, Schipper I, Laven JSE. Serum Anti-Mullerian Hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012; 97:4650-4655.

La Marca A and Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human Reproduction Update. 2014; 20(1): 124–140.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0

Related Articles

Search Authors in












  • Sianny Herawati

  • Sianny Herawati

  • Sianny Herawati